PATENT CLAIM ANALYSIS

Application Number: 16213428
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-10
Patent Classification: ["514", "04400A"]

Abstract:
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.

Claim (Index 26):
The pharmaceutical composition or pharmaceutically acceptable salt thereof of  claim 25 , wherein the antisense oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.04545
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14213607', '14857569', '14852257', '14852264', '14858416']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7036500698216184
- 35 USC 102 Novelty (BERT): 0.5613600958263013
- Combined Prediction Score: 0.6894210724220866
- Mean Citation Score: 407.069126
- Max Citation Score: 447.7007
- Similarity Product: 340.7784898922324

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test